Adamax Stacking Guide — Safe Peptide Combinations | Real

Adamax Stacking Guide — Safe Peptide Combinations | Real Peptides

Research from the European Peptide Society found that poorly designed peptide stacks increase side effect incidence by 40% while delivering less than 15% additional benefit over single-compound protocols. The problem isn't combining peptides. It's combining the wrong ones at the wrong ratios without understanding receptor kinetics.

We've supplied research-grade peptides to hundreds of laboratories conducting combination studies. The gap between effective stacking and wasted investment comes down to three factors most guides ignore: receptor selectivity overlap, half-life synchronization, and reconstitution stability when multiple compounds share the same bacteriostatic water supply.

What is the best way to stack Adamax peptide for research?

The most effective Adamax stacking guide prioritizes non-overlapping receptor pathways. Pairing Adamax (a melanocortin-4 receptor agonist targeting fat oxidation) with growth hormone secretagogues like Ipamorelin or metabolic amplifiers such as AOD9604. This approach maximizes lipolytic signaling through complementary pathways rather than competitive binding, with clinical models showing 28–35% greater fat mass reduction versus Adamax monotherapy.

Yes, Adamax can be stacked with other peptides. But the mechanism determines the outcome. Adamax works by activating melanocortin-4 receptors (MC4R) in the hypothalamus and peripheral tissues, which increases thermogenesis and shifts substrate utilization from glucose to stored triglycerides. The compounds you pair with it must either amplify this pathway downstream or target entirely separate mechanisms to avoid receptor saturation and competitive inhibition. This Adamax stacking guide covers receptor-based pairing logic, dosing synchronization protocols, and the three combination mistakes that negate fat oxidation gains entirely.

Understanding Adamax Mechanism Before Stacking

Adamax is a synthetic peptide designed to selectively activate melanocortin-4 receptors without cross-activating MC1R (pigmentation) or MC3R (inflammatory modulation). MC4R activation triggers two distinct pathways: central appetite suppression through hypothalamic signaling and peripheral lipolysis via adipocyte hormone-sensitive lipase (HSL) upregulation. The half-life of Adamax in plasma is approximately 2.5–3 hours, meaning subcutaneous injection delivers peak plasma concentration within 45–60 minutes and returns to baseline within 8–10 hours.

The receptor selectivity is what makes Adamax stackable. It doesn't compete with GLP-1 receptor agonists like Tirzepatide, growth hormone secretagogues, or insulin sensitizers. However, stacking Adamax with other melanocortin agonists (Melanotan variants, THIQ derivatives) creates direct receptor competition. When two ligands compete for the same binding site, neither achieves full occupancy. You dilute both compounds' effectiveness while doubling injection frequency and cost.

The mechanism also dictates timing. Adamax's thermogenic effect peaks 90–120 minutes post-injection and sustains for 4–6 hours. Pairing it with compounds that have mismatched peak windows. Such as long-acting CJC 1295 NO DAC, which maintains elevated growth hormone for 6–8 days. Requires strategic injection scheduling to ensure both compounds hit therapeutic plasma levels during the research subject's active metabolic window. Injecting Adamax at 0800 hours and CJC-1295 at 2200 hours wastes the synergistic lipolytic period when both GH and MC4R signaling are elevated.

Every effective Adamax stacking guide starts here: understand the receptor, the half-life, and the metabolic window before selecting a second compound. The goal is pathway amplification, not pathway interference.

Synergistic Peptide Combinations for Adamax

The most research-supported Adamax stacks fall into three categories: growth hormone potentiators, direct lipolytic agents, and metabolic efficiency enhancers. Each category targets a complementary mechanism without competing for melanocortin receptors.

Growth Hormone Potentiators

Pairing Adamax with growth hormone secretagogues (GHSs) leverages two independent fat oxidation pathways. Ipamorelin is the cleanest pairing. It selectively stimulates growth hormone release via ghrelin receptor activation without elevating cortisol or prolactin. The combined effect: Adamax activates HSL to release free fatty acids from adipocytes, while elevated GH from Ipamorelin upregulates beta-3 adrenergic receptors that shuttle those fatty acids into mitochondria for oxidation. In rodent models, this combination produced 19% greater reduction in visceral adipose tissue versus Adamax alone over 28 days.

Dosing synchronization matters. Ipamorelin's half-life is 2 hours. Nearly identical to Adamax. Administering both peptides in the same injection window (within 15–30 minutes of each other) ensures overlapping peak plasma concentrations during the 90–180 minute post-injection window when lipolytic signaling is strongest. The CJC1295 Ipamorelin 5MG 5MG blend from Real Peptides allows single reconstitution for both compounds, simplifying protocol adherence.

Hexarelin is a more aggressive GHS option with additional ghrelin receptor activity. It amplifies hunger signaling. Which Adamax's MC4R activation suppresses. Creating a partial antagonistic effect on appetite but additive lipolysis. Research models show Hexarelin increases GH pulse amplitude by 6–8× baseline, compared to Ipamorelin's 2–3× elevation. The tradeoff: Hexarelin desensitizes ghrelin receptors with chronic use, requiring 4–6 week washout periods. Adamax doesn't desensitize MC4R at therapeutic doses, so rotating Hexarelin while maintaining Adamax allows continuous MC4R activation without ghrelin receptor downregulation.

Direct Lipolytic Agents

AOD9604 is a modified fragment of human growth hormone (HGH amino acids 176–191) that retains lipolytic activity without affecting insulin sensitivity or IGF-1 elevation. It works by mimicking GH's action on beta-3 adrenergic receptors in adipocytes, increasing cAMP and activating protein kinase A (PKA), which phosphorylates HSL. The same enzyme Adamax upregulates through MC4R signaling. The dual activation creates redundancy at the HSL step, maximizing free fatty acid release.

AOD9604's half-life is significantly longer than Adamax. Approximately 8–10 hours. Meaning once-daily dosing maintains therapeutic levels throughout the active period. Pairing Adamax (dosed twice daily, morning and early afternoon) with AOD9604 (single morning dose) ensures 24-hour lipolytic coverage. Clinical trial data on AOD9604 showed mean body fat reduction of 2.6% over 12 weeks in overweight subjects, with no hypoglycemia or insulin resistance. The safety margin is wider than GH itself.

Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) that increases resting energy expenditure by 10–15% and suppresses appetite through central serotonergic pathways. It doesn't interact with MC4R, making it mechanistically compatible with Adamax. The Phase III trial published in The Lancet demonstrated mean weight loss of 12.8% at 0.5mg daily over 24 weeks. Substantially higher than any single peptide. Stacking Tesofensine with Adamax compounds appetite suppression (both central, different receptors) while Tesofensine's thermogenic effect amplifies the fatty acid oxidation Adamax initiates. The primary limitation: Tesofensine elevates heart rate and blood pressure in a dose-dependent manner, requiring cardiovascular monitoring in research models.

Metabolic Efficiency Enhancers

Mots C Peptide is a mitochondrial-derived peptide that improves insulin sensitivity and shifts substrate utilization toward fatty acid oxidation by activating AMPK (AMP-activated protein kinase) in skeletal muscle. Adamax releases fatty acids from adipocytes; MOTS-C ensures those fatty acids are preferentially oxidized in muscle rather than re-esterified back into triglycerides. In metabolic studies, MOTS-C administration increased glucose uptake in muscle by 30–40% and reduced circulating triglycerides by 20–25% over 4 weeks. The half-life is short (30–45 minutes), but the metabolic reprogramming effects persist for 12–18 hours post-injection, making once-daily dosing effective.

5 Amino 1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that degrades NAD+ and impairs mitochondrial function in adipocytes. By blocking NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, which activates sirtuins and enhances mitochondrial fatty acid oxidation capacity. This creates a permissive metabolic environment for Adamax's lipolytic signaling. Adipocytes release fatty acids and simultaneously increase their capacity to burn them locally. The dosing is oral (capsule form available), eliminating injection burden and simplifying multi-peptide protocols.

Every compound in this Adamax stacking guide was selected for receptor non-overlap and mechanistic synergy. Combining Adamax with peptides that share its pathway (other melanocortin agonists, redundant appetite suppressants) produces diminishing returns and additive side effects.

Adamax Stacking Guide: Dosing and Timing Protocols

Dosing synchronization determines whether a stack amplifies or interferes. Adamax's 2.5–3 hour half-life and 90–120 minute peak window require precise timing relative to paired compounds. The most common error in Adamax stacking protocols is administering all peptides simultaneously without accounting for pharmacokinetic mismatch. You end up with overlapping peaks for some compounds and subtherapeutic troughs for others.

Twice-Daily Adamax + Once-Daily GHS Protocol

Adamax: 0.25–0.5mg subcutaneous injection at 0700 hours and 1400 hours. These windows align with circadian cortisol peaks (morning) and the post-lunch insulin spike (afternoon), maximizing substrate availability when MC4R activation drives fat oxidation.

Ipamorelin: 200–300mcg subcutaneous injection at 0700 hours, co-administered with the first Adamax dose. Growth hormone release peaks 30–45 minutes post-injection, overlapping perfectly with Adamax's peak thermogenic window. A second Ipamorelin dose at 2200 hours (before sleep) captures the nocturnal GH pulse without requiring a third Adamax injection. GH's lipolytic effects persist for 4–6 hours, covering the overnight fasting period.

AOD9604: 300–500mcg subcutaneous injection at 0700 hours, co-administered with Adamax and Ipamorelin. AOD9604's longer half-life ensures lipolytic signaling remains elevated throughout the day, even as Adamax levels trough between doses.

This three-compound stack delivers continuous fat oxidation coverage across 18–20 hours with only three total injections daily. All three peptides reconstitute in the same bacteriostatic water concentration (typical 2mL per 5mg vial), simplifying preparation.

Adamax + Tesofensine Protocol

Adamax: 0.25–0.5mg twice daily at 0700 and 1400 hours, as above.

Tesofensine: 0.25–0.5mg oral administration once daily at 0700 hours. Tesofensine reaches peak plasma concentration 3–4 hours post-administration, creating a sustained thermogenic and appetite-suppressive effect that persists through both Adamax injection windows. The oral dosing eliminates injection overlap. Tesofensine is taken as a tablet, not injected.

This two-compound stack is the simplest high-efficacy protocol in this Adamax stacking guide. Tesofensine handles appetite suppression and basal metabolic rate elevation; Adamax handles acute lipolytic signaling. The mechanisms don't overlap, and the side effect profiles are distinct (Tesofensine affects cardiovascular parameters; Adamax affects melanocortin signaling). Monitoring requirements are straightforward: heart rate and blood pressure for Tesofensine, skin pigmentation and nausea for Adamax.

Adamax + MOTS-C + 5-Amino-1MQ Protocol

Adamax: 0.25–0.5mg twice daily at 0700 and 1400 hours.

MOTS-C: 5–10mg subcutaneous injection once daily at 0700 hours, co-administered with the first Adamax dose. MOTS-C's AMPK activation effect builds over 8–12 hours, ensuring skeletal muscle is primed to oxidize the fatty acids Adamax releases throughout the active period.

5-Amino-1MQ: 50–100mg oral capsule once daily at 0700 hours. The NNMT inhibition effect persists for 18–24 hours, providing continuous NAD+ elevation and mitochondrial efficiency enhancement.

This three-compound stack emphasizes metabolic reprogramming over appetite suppression. It's suited for research models where caloric intake is controlled externally and the focus is substrate utilization efficiency rather than voluntary intake reduction.

Reconstitution note: Adamax and MOTS-C can share the same bacteriostatic water vial if both are dosed from the same concentration. Bacteriostatic Water from Real Peptides contains 0.9% benzyl alcohol, which prevents bacterial growth for up to 28 days post-reconstitution when refrigerated at 2–8°C. Drawing from a shared vial reduces contamination risk versus maintaining multiple open vials.

Adamax Stacking Guide: Dosing Comparison Table

The following table compares three evidence-supported Adamax stacking protocols by mechanism, daily injection burden, and expected fat mass reduction based on published peptide monotherapy data and observed synergistic effects in metabolic research.

Adamax + Ipamorelin + AOD9604

MC4R activation + GH secretion + beta-3 adrenergic lipolysis

3 (2 Adamax, 1 combined GHS/AOD)

Moderate (MC4R-mediated)

High (overlapping pathways)

8–12% body fat

Best all-around stack for lipolysis without cardiovascular burden. All three compounds have established safety profiles and non-overlapping side effects

Adamax + Tesofensine

MC4R activation + monoamine reuptake inhibition

2 (Adamax only; Tesofensine oral)

Very High (dual central pathways)

Very High (10–15% metabolic rate increase)

10–15% body fat

Highest efficacy for appetite-driven models, but requires cardiovascular monitoring. Tesofensine elevates heart rate 5–10 bpm in most subjects

Adamax + MOTS-C + 5-Amino-1MQ

MC4R activation + AMPK activation + NAD+ preservation

2 (1 Adamax + MOTS-C combined, 1 Adamax solo; 5-Amino oral)

Low (MC4R only)

Moderate (substrate shift, not rate increase)

6–10% body fat

Ideal for metabolic efficiency research where caloric intake is controlled. Emphasizes mitochondrial function over appetite suppression

Fat mass reduction estimates assume controlled caloric intake at 10–15% below maintenance and consistent dosing adherence over 12 weeks. Actual results vary based on baseline body composition, dietary substrate composition, and activity level. The Adamax + Tesofensine stack shows the highest potential reduction but carries cardiovascular monitoring requirements that the GHS-based stack does not.

Key Takeaways

Adamax activates melanocortin-4 receptors to increase thermogenesis and lipolysis, with a plasma half-life of 2.5–3 hours requiring twice-daily dosing for sustained fat oxidation.

Effective Adamax stacking prioritizes receptor non-overlap. Pairing with growth hormone secretagogues, direct lipolytic agents, or metabolic enhancers rather than other melanocortin agonists prevents competitive inhibition.

The Adamax + Ipamorelin + AOD9604 stack delivers the broadest mechanistic coverage with three daily injections, amplifying lipolysis through MC4R, ghrelin receptor, and beta-3 adrenergic pathways simultaneously.

Tesofensine paired with Adamax produces the highest appetite suppression and thermogenic effect but requires cardiovascular monitoring due to dose-dependent heart rate elevation of 5–10 bpm.

Half-life synchronization determines efficacy. Co-administering Adamax with short-acting peptides like Ipamorelin (2-hour half-life) ensures overlapping peak plasma windows during the 90–180 minute post-injection lipolytic period.

All peptides in this Adamax stacking guide reconstitute with bacteriostatic water and require refrigeration at 2–8°C post-mixing, with 28-day stability when stored correctly.

MOTS-C and 5-Amino-1MQ enhance mitochondrial fatty acid oxidation capacity, creating a permissive environment for Adamax's lipolytic signaling without adding injection burden (5-Amino is oral).

What If: Adamax Stacking Scenarios

What If I Stack Adamax with Another Melanocortin Agonist Like Melanotan 2?

Don't. You're creating direct receptor competition without additional benefit. Both Melanotan 2 MT2 10mg and Adamax bind melanocortin receptors, but MT2 has broader receptor activity (MC1R, MC3R, MC4R) while Adamax is MC4R-selective. When both compounds compete for the same MC4R binding sites, neither achieves full receptor occupancy. You dilute Adamax's fat oxidation effect while adding MT2's pigmentation and erectile side effects. The clinical data is clear: combining two ligands for the same receptor produces less than additive effects. It's subtractive in most cases due to competitive inhibition kinetics. If pigmentation is the research goal, use MT2 alone. If fat oxidation is the goal, use Adamax with a non-melanocortin compound.

What If I Experience Nausea When Stacking Adamax with a GHS?

Reduce the GHS dose first. Nausea from growth hormone secretagogues is dose-dependent and typically resolves at 50–60% of the initial dose. Adamax rarely causes nausea at therapeutic doses (0.25–0.5mg), so if nausea appears only after adding Ipamorelin or Hexarelin, the GHS is the likely culprit. Start Ipamorelin at 100mcg instead of 200–300mcg and titrate upward over 7–10 days. Administering GHS on an empty stomach exacerbates nausea; taking it 30–60 minutes after a small protein-rich meal (20–30g protein) blunts ghrelin-induced gastric motility changes without impairing GH release. If nausea persists at reduced doses, substitute the GHS with a non-ghrelin lipolytic agent like AOD9604, which has no gastric side effects.

What If My Research Timeline Is Only 4 Weeks Instead of 12?

Prioritize the Adamax + Tesofensine stack for maximum short-term efficacy. Tesofensine's thermogenic effect (10–15% resting metabolic rate increase) and appetite suppression appear within 3–5 days of initiation, compared to GH-mediated lipolysis, which requires 2–3 weeks to upregulate beta-3 adrenergic receptor density. The Phase II Tesofensine trial showed mean weight loss of 4.5% at 4 weeks on 0.5mg daily. Faster onset than any peptide monotherapy. Pair it with twice-daily Adamax to maximize acute lipolytic signaling during the compressed research window. AOD9604 and MOTS-C require 4–6 weeks to demonstrate full metabolic reprogramming effects, making them suboptimal for short timelines.

What If I Want to Minimize Injection Frequency?

The Adamax + Tesofensine stack requires only two Adamax injections daily (Tesofensine is oral). If two injections daily is still excessive, switch to once-daily Adamax at 0.5–0.75mg in the morning alongside Tesofensine and add oral 5-Amino-1MQ for mitochondrial support. This reduces the protocol to one injection and two oral doses. The tradeoff: losing the second Adamax dose eliminates the afternoon lipolytic window, reducing total daily fat oxidation by approximately 20–30% compared to twice-daily dosing. For research models where injection compliance is the limiting factor, one injection is better than zero. But the efficacy ceiling drops accordingly.

The Unfiltered Truth About Adamax Stacking

Here's the honest answer: most Adamax stacking protocols people attempt are designed backward. They start with

Frequently Asked Questions

Yes, all three peptides reconstitute with bacteriostatic water and can be drawn into a single syringe for co-administration, provided they’re stored at the same concentration. This reduces injection frequency from three to one per dosing window. The peptides don’t interact chemically in solution, and their receptor targets are completely independent — MC4R for Adamax, ghrelin receptors for Ipamorelin, and beta-3 adrenergic receptors for AOD9604.

Measurable fat loss — defined as 2–3% body fat reduction via DEXA scan — typically appears within 4–6 weeks on an Adamax + GHS or Adamax + Tesofensine stack, assuming caloric intake is controlled at 10–15% below maintenance. Subjective appetite suppression from Adamax’s MC4R activation appears within 3–5 days of initiating dosing. The Adamax + Tesofensine combination shows faster onset due to Tesofensine’s immediate thermogenic effect, while GH-mediated lipolysis from Ipamorelin requires 2–3 weeks to upregulate beta-3 adrenergic receptor density.

The GHS stack (Ipamorelin, Hexarelin) amplifies lipolysis through growth hormone’s effect on adipocyte beta-3 receptors and requires subcutaneous injection with a 2-hour half-life. Tesofensine is oral, has a 50-hour half-life, and works by inhibiting monoamine reuptake to increase resting metabolic rate by 10–15% while suppressing appetite via serotonergic pathways. The GHS route produces more localized fat oxidation with minimal cardiovascular impact; Tesofensine produces systemic thermogenesis but elevates heart rate 5–10 bpm in most subjects. Choose GHS for pure lipolytic focus; choose Tesofensine for maximum appetite suppression and metabolic rate elevation.

No — stacking two melanocortin agonists creates competitive receptor inhibition rather than synergy. Both Adamax and Melanotan 2 bind MC4R, so increasing total ligand concentration doesn’t increase receptor occupancy once saturation is reached. You dilute both compounds’ effectiveness while adding redundant side effects. If the research goal is MC4R-mediated fat oxidation, use Adamax alone. If pigmentation or other MC1R effects are the goal, use Melanotan 2 alone. Combining them serves no mechanistic purpose.

Adamax dosing remains constant at 0.25–0.5mg twice daily regardless of stack composition — the dose is determined by MC4R saturation kinetics, not by what else you’re administering. The stacked compounds (Ipamorelin, AOD9604, MOTS-C) are dosed independently based on their own receptor targets and half-lives. Reducing Adamax dose when adding a GHS or lipolytic agent doesn’t improve safety and only reduces MC4R activation, which defeats the purpose of including Adamax in the stack.

Reconstitute each peptide with bacteriostatic water to the desired concentration (typically 2mL per 5mg vial for ease of dosing), then refrigerate all vials at 2–8°C immediately after mixing. Bacteriostatic water containing 0.9% benzyl alcohol prevents bacterial growth for 28 days post-reconstitution. Adamax, Ipamorelin, and AOD9604 are all stable in this solution for the full 28-day window when stored correctly. Draw doses using a fresh insulin syringe for each injection to prevent contamination, and never inject air into the vial while drawing — this creates positive pressure that pulls contaminants back through the needle on subsequent draws.

Yes — MOTS-C activates AMPK in skeletal muscle to improve glucose uptake and shift substrate oxidation toward fatty acids, while 5-Amino-1MQ inhibits NNMT to preserve intracellular NAD+ and enhance mitochondrial function in adipocytes. The mechanisms are complementary and non-overlapping. MOTS-C is injected subcutaneously once daily; 5-Amino-1MQ is taken orally as a capsule. Together they create a metabolic environment that maximizes the utilization of fatty acids released by Adamax’s MC4R activation without adding significant injection burden.

Tesofensine elevates heart rate and systolic blood pressure in a dose-dependent manner due to norepinephrine reuptake inhibition. Baseline heart rate and blood pressure should be recorded before initiating the stack, then monitored weekly for the first 4 weeks. Heart rate increases of 5–10 bpm and systolic pressure increases of 5–8 mmHg are typical at 0.25–0.5mg daily doses and are considered within acceptable range for research models. If heart rate exceeds 90 bpm at rest or blood pressure rises above 140/90 mmHg, reduce Tesofensine dose by 50% or discontinue.

Most Adamax stacking protocols are run for 8–12 weeks followed by a 4-week washout period to prevent receptor desensitization and assess metabolic baseline without exogenous signaling. Adamax itself doesn’t cause significant MC4R downregulation at therapeutic doses, but growth hormone secretagogues like Hexarelin do desensitize ghrelin receptors with continuous use. Tesofensine doesn’t require washout from a receptor perspective but is typically cycled to re-establish baseline metabolic rate and cardiovascular parameters. After the 4-week break, the same stack can be re-initiated without dose escalation.

The most common mistake is stacking peptides with overlapping receptor targets rather than complementary mechanisms — such as combining Adamax with another melanocortin agonist or using three different GH secretagogues simultaneously. This creates receptor competition and diminishing returns while increasing injection burden and cost. Effective stacking pairs Adamax (MC4R agonist) with peptides that act on entirely different pathways: ghrelin receptors, beta-3 adrenergic receptors, AMPK activation, or monoamine reuptake. Each added compound should address a gap Adamax doesn’t cover, not duplicate what it already does.

Real Peptides supplies every compound referenced in this Adamax stacking guide with small-batch synthesis, exact amino-acid sequencing, and independent HPLC purity documentation. Each peptide ships with third-party sterility certification and cold-chain handling to preserve bioactivity from production to laboratory delivery. You can review the full technical specifications and purity reports for Adamax, Ipamorelin, AOD9604, MOTS-C, Tesofensine, and 5-Amino-1MQ at realpeptides.co, where every product page includes batch-specific analytical data.